Advertisement

Topics

More Information Requested from Dynavax Concerning Hepatitis B Vaccine

14:57 EDT 4 Aug 2017 | PharmPro

Dynavax provides U.S. regulatory update on HEPLISAV-B following FDA advisory committee meeting. The FDA has delayed a decision on the hepatitis B vaccine, requesting further details about the proposed post-marketing study for the drug.
Contributed Author: 
Dynavax Technologies Corporation
Topics: 

Original Article: More Information Requested from Dynavax Concerning Hepatitis B Vaccine

NEXT ARTICLE

More From BioPortfolio on "More Information Requested from Dynavax Concerning Hepatitis B Vaccine"

Quick Search
Advertisement
 

Relevant Topics

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...

Gastroenterology
Astroesophageal Reflux Disease (GERD) Barrett's Esophagus Celiac Disease Cholesterol Crohn's Disease Gastroenterology Hepatitis Hepatology Irritable Bowel Syndrome (IBS) Pancreatitis Peptic Ulcer Disease...